Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$29.26 USD

29.26
6,646,430

-0.49 (-1.65%)

Updated May 2, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arpita Dutt headshot

Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News

by Arpita Dutt

The sector was once again slammed by president-elect Donald Trump's comments this week regarding drug pricing.

    Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.

    by Zacks Equity Research

    Mylan (MYL) and Biocon Ltd. announced that the FDA had accepted the BLA for their biosimilar version of Herceptin (trastuzumab), MYL-1401O.

      by Zacks Equity Research

        Roche Gets Priority Review for Immunotherapy Drug Tecentriq

        by Zacks Equity Research

        Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.

          Arpita Dutt headshot

          The FDA Approved Fewer Drugs in 2016: Here's Why

          by Arpita Dutt

          Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?

            Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication

            by Zacks Equity Research

            Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.

              Mylan/Biocon's Herceptin Biosimilar Phase III Data Published

              by Zacks Equity Research

              Mylan (MYL) and partner Biocon's biosimilar version of Herceptin phase III data published in JAMA.

                Roche (RHHBY) Hemophilia A Drug Positive in Phase III

                by Zacks Equity Research

                Roche (RHHBY) announced that the phase III study, HAVEN 1, met its primary endpoint.

                  Arpita Dutt headshot

                  Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe

                  by Arpita Dutt

                  J&J (JNJ) and Actelion are back in the limelight with the companies in exclusive talks regarding a possible deal.

                    Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx

                    by Zacks Equity Research

                    Exelixis, Inc. (EXEL) announced that it has amended the exclusive collaboration and licensing agreement with its European partner Ipsen.

                      Merrimack (MACK) Drops as Breast Cancer Drug Trial Stops

                      by Zacks Equity Research

                      Shares of Merrimack Pharmaceuticals, Inc. (MACK) tanked 18.4% after the company announced the discontinuation of a phase II trial on its breast cancer candidate, MM-302.

                        Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU

                        by Zacks Equity Research

                        Pfizer Inc. (PFE) announced that the European Commission has approved an expanded indication for its meningococcal vaccine, Nimenrix.

                          Roche (RHHBY) MS Drug FDA Review Date Extended in U.S.

                          by Zacks Equity Research

                          Roche (RHHBY) announced that the FDA has extended the PDUFA date for the review of the company's Biologics License Application (BLA) for Ocrevus.

                            Roche (RHHBY) to Terminate Pacifica Bioscience Agreement

                            by Zacks Equity Research

                            Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.

                              Merck (MRK) Offers Update on Keytruda-Halaven Combination

                              by Zacks Equity Research

                              Merck (MRK) and Eisai (ESALY) announced new interim data from a phase Ib/II study on the Keytruda-Halaven combination for the treatment of metastatic TNBC.

                                Ophthotech Hits 52-Week Low on Unfavorable Fovista Data

                                by Zacks Equity Research

                                Ophthotech's (OPHT) shares tumbled 86.4% to a 52-week low after the company reported disappointing phase III data on its eye drug, Fovista, in wet AMD patients.

                                  Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval

                                  by Zacks Equity Research

                                  Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.

                                    Biogen Presents Positive Early Data from Alzheimer's Study

                                    by Zacks Equity Research

                                    Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.

                                      Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

                                      by Zacks Equity Research

                                      Novartis (NVS) announced results from the phase III ASCEND-4 study on Zykadia, for the treatment of patients with advanced ALK+ NSCLC.

                                        Roche Presents Positive Follicular Lymphoma Data on Gazvya

                                        by Zacks Equity Research

                                        Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.

                                          Kite Pharma Begins Filing for KTE-C19, Presents Data at ASH

                                          by Zacks Equity Research

                                          Kite Pharma, Inc. (KITE) announced it has initiated a rolling submission of the Biologic License Application (BLA) for its lead pipeline candidate, KTE-C19, to the FDA.

                                            Amgen/Allergan File for EU Approval of Avastin Biosimilar

                                            by Zacks Equity Research

                                            Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

                                              Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

                                              by Zacks Equity Research

                                              Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

                                                Merck KGaA (MKGAF) Expands Distribution Deal with Roche

                                                by Zacks Equity Research

                                                Merck (MKGAF) announced that it has expanded the distribution alliance with Roche (RHHBY) to include enzyme products ??? PCR and qPCR.

                                                  Arpita Dutt headshot

                                                  Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda

                                                  by Arpita Dutt

                                                  This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.